Significance of topoisomerase IIIβ expression in breast ductal carcinomas: Strong associations with disease-specific survival and metastasis

Human Pathology

Volumn 41, Issue 11, 2010, Pages 1624-1630

  Oliveira Costa, João Paulo ^a   Zanetti, Juliana ^a   Oliveira, Lucinei Roberto ^a   Soares, Fernando Augusto ^b   Ramalho, Leandra Zambelli ^a   Silva Ramalho, Fernando ^a   Garcia, Sérgio Britto ^a   Ribeiro Silva, Alfredo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Breast cancer; Immunohistochemistry; Prognosis; Topoisomerase III

Indexed keywords

BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; DNA TOPOISOMERASE III BETA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN P53; UNCLASSIFIED DRUG; DNA TOPOISOMERASE III; ISOENZYME; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; AGED; BRAZIL; BREAST TUMOR; CANCER STAGING; CHROMOSOME ANALYSIS; ENZYMOLOGY; EPIDEMIOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PAGET NIPPLE DISEASE; PATHOLOGY; SECONDARY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BRAZIL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; CYTOGENETIC ANALYSIS; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; IN SITU HYBRIDIZATION; ISOENZYMES; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77957940286     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.01.027     Document Type: Article

References (32)

1. Champoux J.J. DNA topoisomerases: structure, functions and mechanism Annu Rev Biochem 70 2001 369 413
2. Forterre P., Gribaldo S., Gadelle D., and Serre M.C. Origin and evolution of DNA topoisomerases Biochimie 89 2007 427 446
3. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective Nat Rev Cancer 3 2002 430 440
4. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond Nat Rev Cancer 6 2006 789 802
5. Lodge A.J., Anderson J.J., and Ng S.W. Expression of topoisomerase IIIα in normal and neoplastic tissues determined by immunohistochemistry using a novel monoclonal antibody Br J Cancer 83 2000 498 505
6. Kawasaki K., Minoshima S., and Nakato E. One-megabase sequence analysis of the human immunoglobulin lambda gene locus Genome Res 7 1997 250 261
7. Wilson-Sali T., and Hsieh T.S. Preferential cleavage of plasmid-based R-loops and D-loops by Drosophila topoisomerase IIIbeta Proc Natl Acad Sci 99 2002 7974 7979
8. Kwan K.Y., Moens P.B., and Wang J.C. Infertility and aneuploidy in mice lacking a type IA DNA topoisomerase III beta Proc Natl Acad Sci 100 2003 2526 2531
9. Kwan K.Y., and Wang J.C. Mice lacking DNA topoisomerase IIIbeta develop to maturity but show a reduced mean lifespan Proc Natl Acad Sci 98 2001 5717 5721
10. Kwan K.Y., Greenwald R.J., and Mohanty S. Development of autoimmunity in mice lacking topoisomerase IIIβ Proc Natl Acad Sci 104 2007 9242 9247
11. Mohanty S., Town T., and Yagi T. Defective p53 engagement after the induction of DNA damage in cells deficient in topoisomerase IIIβ Proc Natl Acad Sci 105 2007 5063 5068
12. Fitzgibbons P.L., Page D.L., and Weaver D. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999 Arch Pathol Lab Med 124 2000 966 978
13. Di Leo A., Larsimont D., and Gancberg D. HER-2 and topoisomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide Ann Oncol 12 2001 1081 1089
14. Mangia A., Chiriatti A., and Tommasi S. BRCA1 expression and molecular alterations in familial breast cancer Histol Histopathol 24 2009 69 76
15. Wolff A.C., Hammond M.E., and Schwartz J.N. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 2007 18 43
16. MacGrogan G., Rudolph P., and de Mascarel I. DNA topoisomerase IIα expression and the response to chemotherapy in breast cancer Br J Cancer 89 2003 666 671
17. Hafian H., Venteo L., and Sukhanova A. Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase IIα, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas Hum Pathol 35 2004 745 751
18. Doussis-Anagnostopoulou I.A., Vassilakopoulos T.P., and Thymara I. Topoisomerase IIα expression as an independent prognostic factor in Hodgkin's lymphoma Clin Cancer Res 14 2008 1759 1766
19. Gerdes J., Lemke H., and Baisch H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67 J Immunol 133 1984 1710 1715
20. Kobayashi M., and Hanai R. M phase-specific association of human topoisomerase IIIbeta with chromosomes Biochem Biophys Res Commun 287 2001 282 287
21. Mano M.S., Rosa D.D., and De Azambuja E. The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours Cancer Treat Rev 33 2007 64 77
22. Hengstler J.G., Lange J., and Kett A. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer Cancer Res 59 1999 3206 3214
23. Park D.I., Yun J.W., and Park J.H. HER-2/neu amplification is an independent prognostic factor in gastric cancer Dig Dis Sci 51 2006 1371 1379
24. Jaehne M., Roeser K., and Jaekel T. Clinical and immunohistologic typing of salivary duct carcinoma Cancer 103 2005 2526 2533
25. O'Malley F.P., Chia S., and Tu D. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy J Natl Cancer Inst 101 2009 644 650
26. Pritchard K.I., Messersmith H., and Elavathil L. HER-2 and topoisomerase II as predictors of response to chemotherapy J Clin Oncol 26 2008 736 744
27. Järvinen T.A., Tanner M., and Bärlund M. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer Genes Chromosomes Cancer 26 1999 142 150
28. Arriola E., Rodriguez-Pinilla S.M., and Lambros M.B. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer Breast Cancer Res Treat 106 2007 181 189
29. Perou C.M., Sorlie T., and Eisen M.B. Molecular portraits of human breast tumors Nature 406 2000 747 752
30. Ignatiadis M., Desmedt C., and Sotiriou C. HER-2 as a target for breast cancer therapy Clin Cancer Res 15 2009 1848 1852
31. Brosh R., and Rotter V. When mutants gain new powers: news from the mutant p53 fields Nat Rev Cancer 9 2009 701 713
32. Venkitaraman A.R. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment Annu Rev Pathol Mech Dis 4 2009 461 487